EBMT 2023 | Targeting tumor cells through non-viral Sleeping Beauty transposon engineered CD19-CAR-NK cells
In this video, Tobias Bexte, Goethe University Frankfurt, Frankfurt, Germany, comments on the design, safety, and efficacy of non-viral Sleeping Beauty (SB) transposon engineered CD19-CAR-natural killer (NK) cells for the treatment of leukemia. Mr Bexte explains that prior experiments have shown that NK cells do not cause graft-versus-host disease (GvHD), cytokine release syndrome (CRS), and neurotoxicity and represent a promising and innovative cell type for cell therapy. Dr Bexte gives an overview of the protocol for the engineering of these cells and explains that both in vitro and in vivo experiments have shown that this product has a safe genomic integration profile and is highly effective against tumor cells. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
